BIA Networking Breakfast - Cambridge
Join us on Thursday 22 March for another popular BIA networking breakfast. This is an ideal opportunity to meet new business contacts, network with members and hear from local members.
We welcome you to join the VWR/BIA networking and workshop event on 21st March - read more here
Babraham Research Campus
08:30 - 09:30 Registration, breakfast and networking
09:30 Introduction, BIA update Steve Bates
09.40 Recent developments and future plans in the Cambridge region Tony Jones
09.50 Stratagem IPM Nicola Baker-Munton
10.00 F-star: A Case Study for a Biotech Business Model Jane Dancer
10.15 Mission Therapeutics Anker Lundemose
10:30 - 11:00 Further networking
Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry and Translation Committee.
Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations. An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. Steve was awarded the OBE in January 2017.
Nicola Baker-Munton is the founder and Chief Executive Officer of Stratagem IPM. She is a Chartered UK Patent Attorney and European Patent Attorney with a joint honours degree in biology and biochemistry. During her nine years as an industrial practitioner at the Wellcome Foundation Limited, and four years in the private sector, Nicola recognised the need for much greater assistance with management of intellectual property earlier in the development of technologies, and advice and assistance with commercialisation throughout the technology/product life-cycle.
Nicola founded Stratagem IPM in 1999. With Steady growth it has become the leading specialist company providing active strategic management of intellectual property portfolios from inception through development to market, and from academia through startup to stock market listing.
Dr Jane Dancer
Jane has over 15 years’ experience in business development gained from roles in both biotech and pharma. Since joining F-star in late 2011 Jane has led a series of significant and innovative transactions with BMS, AbbVie, Denali and Merck (EMD Serono) raising almost $200M in non-dilutive financing and advancing F-star’s drug pipeline. By establishing asset-centric-vehicles as well as more traditional licensing, F-star has been able to realise the value of its individual assets through flexible deal structuring. As well as business development, Jane is responsible for transactional legal matters, IP and Communications at F-star. Earlier this year she was identified by Labiotech as one of the 15 Women Leading in European Biotech.
Prior to F-star, she held business development positions at Cellzome and Cambridge Antibody Technology (CAT). At Cellzome she led two significant transactions with GSK; Cellzome was subsequently acquired by GSK in 2012. During her time at CAT she led negotiations on multiple significant transactions, subsequently continuing this work within AstraZeneca following the acquisition of CAT.
She has a first class degree, a PhD and an MBA from the University of Cambridge and spent the first part of her career within the agrochemical industry. She is Vice-Chair of the Sir Richard Stapley Educational Trust, a member of the University of Cambridge Careers Service Syndicate and an Associate of Newnham College.
Dr Anker Lundemose
In a biopharma career spanning over twenty five years, Dr. Lundemose brings extensive international experience in areas of management, business and corporate development, M&A strategy, and execution, financing, as well as R&D in key therapeutic areas including oncology, neuroscience, diabetes, obesity and anti-infectives. He is an entrepreneur and founder of several successful biotech companies. He is on the board of Inthera Therapeutics and Antag Therapeutics.
Prior to Mission Therapeutics, Dr. Lundemose was CEO of publicly listed Bionor Pharma, and owner and Managing Partner of BioTesch Advice & Consultancy. Previously he was co-founder and CEO of Prosidion, the UK spin-out of OSI Pharmaceuticals’ diabetes and obesity assets, which was reversed into OSI Pharmaceuticals, Inc. At OSI Pharmaceuticals, Dr. Lundemose held several senior management roles, most latterly as Executive Vice President Corporate Development & Strategy Officer, OSI, New York. He was responsible for the acquisition of the DP-IV patent estate from Probiodrug generating 30 times return on investment. He was also involved in the sale of OSI Pharmaceuticals to Astellas Pharma for $4 billion.
Dr. Lundemose has been involved in six biotech exits/IPOs and has held Board positions on over 12 Biotech Companies.
Dr. Lundemose is a qualified medical doctor and has a D.M.Sc and a Ph.D from the University of Aarhus, Denmark.